Peripheral T-cell lymphoma, not otherwise specified, is a broad category of biologically and
clinically heterogeneous diseases that cannot be further classified into any other of the …

Historical advances in the care of patients with non‐Hodgkin lymphoma (NHL) have been
restricted largely to patients with B‐cell lymphoma. The peripheral T‐cell lymphomas …

Purpose Systemic peripheral T-cell lymphomas (PTCLs) respond poorly to conventional
therapy. To evaluate the efficacy of a dose-dense approach consolidated by up-front high …

Peripheral T-cell lymphomas (PTCLs) are rare lymphomas with mostly poor outcome with
current treatment. The addition of etoposide to cyclophosphamide, doxorubicin, vincristine …

Purpose Peripheral T-cell lymphomas (PTCLs) are rare malignancies with poor outcome
after conventional chemotherapy. The role of myeloablative therapy and autologous stem …

Purpose To analyze outcomes of hematopoietic cell transplantation (HCT) in T-cell non-
Hodgkin lymphoma. Patients and Methods Outcomes of 241 patients (112 anaplastic large …

Purpose Front-line treatment of peripheral T-cell lymphomas (PTCL) involves regimens such
as cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and results in a 5-year …

Background Peripheral T-cell lymphoma (PTCL) remains a therapeutic challenge. Due to
the rarity and the heterogeneity of PTCL, no consensus has been achieved regarding even …

Background The role of autologous stem cell transplantation (ASCT) in the first complete
remission (CR1) of peripheral T‐cell lymphomas (PTCLs) is not well defined. This study …

Summary Peripheral T‐Cell lymphomas (PTCL) are relatively rare diseases but appear to be
highly aggressive and display worse remission and survival rates than B‐cell lymphomas …